Navigation Links
UCSF team discovers key to fighting drug-resistant leukemia
Date:5/18/2011

Doctors who treat children with the most common form of childhood cancer acute lymphoblastic leukemia are often baffled at how sometimes the cancer cells survive their best efforts and the most powerful modern cancer drugs.

Now a team of scientists led by researchers at the University of California, San Francisco have uncovered the basis for this drug resistance: BCL6, a protein that leukemia cells use to stay alive. Targeting this protein may be the key to fighting drug-resistant leukemia, a discovery that may make cancer drugs more powerful and help doctors formulate powerful drug cocktails to cure more children of leukemia.

"We believe this discovery is of immediate relevance to patient care," said Markus Mschen, MD, PhD, a professor of laboratory medicine at UCSF and the senior author on the study.

As described in the journal Nature this week, Mschen and his colleagues showed that mice with drug-resistant leukemia can be cured of the disease when given conventional cancer drugs in combination with a compound that disables the BCL6 protein. This compound was initially developed by Ari Melnick, a professor of pharmacology at the Weill Cornell College of Medicine in New York and a co-author of the study.

A COMMON FORM OF CANCER IN CHILDREN

Acute lymphoblastic leukemia is the most common form of cancer in children and accounts for about 23 percent of all cases of cancer in children under the age of 15, according to the National Cancer Institute.

In this form of cancer, leukemia cells in the bloodstream and bone marrow continuously multiply, crowding out other, healthy cells. The disease progresses rapidly, and the leukemia cells begin to infiltrate tissues in other parts of the body. Treatment is neither cheap nor easy but it can be miraculous. It usually involves a long course of drugs that can be physically and emotionally taxing for the children and their parents. Once finished, many enjoy complete remission and are able to live cancer-free, cured of the leukemia.

Still a large number of children are not cured and ultimately succumb to the disease. In those cases, some of the cancer cells resist the therapy and survive quietly in the body. When the cancer reemerges, it is no longer sensitive to the drugs.

In their new report, Mschen and his colleagues show that the key to this resistance is the protein BCL6, offering the first evidence of how the cancer cells managed to survive.

"It is something like an emergency mechanism whereby tumor cells try to evade drug-treatment," Mschen said.

ONE AMONG 22,000 GENES

The work started four years ago when Mschen wanted to figure out what happens to cancer cells during cancer treatments. He and his colleagues exposed leukemia cells in the petri dish to drugs and then looked at how they responded to the treatment. They analyzed how the expression of 22,000 different genes changed when different cancer cells were given different drugs, and they found that BCL6 levels always rocketed up following treatment.

The BCL6 protein was already known to cancer researchers because it is active in other forms of cancer. In lymphoma, for instance, BCL6 protects cancer cells from dying, and the protein has long been the target for research and drug design. But it had never been connected to leukemia.

Reasoning that blocking BCL6 would make leukemia cells more sensitive to chemotherapy, the scientists showed exactly that. Working with Melnick and colleagues at Weill-Cornell Medical College in New York City who had developed a biotech drug-like peptide that blocks BCL6, they showed that giving the peptide to mice along with anti-leukemia drugs increased the potency of conventional drugs and helped the mice survive the disease.

Now Mschen is looking for ways to do the same thing with small molecules, which are generally easier to formulate into an oral drug and cheaper to mass produce than biotech drugs like peptides.

Last year, he was awarded a $3.6 million grant from the California Institute for Regenerative Medicine (CIRM) to develop such a molecule.


'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-4608
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. UCSF team discovers new way to predict breast cancer survival and enhance effectiveness of treatment
2. OHSU Doernbecher discovers new approach to drug resistance in aggressive childhood cancer
3. MU chemist discovers shortcut for processing drugs
4. deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer
5. UT professor defines play, discovers even turtles need recess
6. Research discovers how the deaf have super vision
7. Colorado researcher discovers mechanism for changing adult cells into stem-like cells
8. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
9. TGen-Mayo Clinic study discovers role of DNA methylation in multiple myeloma blood cancer
10. Virginia Tech professor discovers new TB pathogen
11. UCSF-led team discovers familial link in rare childhood leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... ... Recognizing that lifestyle medicine is essential to health and healthcare, About.com ... MD, MPH, president of the American College of Lifestyle Medicine, as their first senior ... said Katz. “There is so much opportunity to add years to lives, and life ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare ... Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and reality ... breast cancer that occurs in the milk ducts, according to an interview with ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... support for knees, ankles, and elbows. Engineered with athletes in mind, OMNIFORCE ... manufacturing (opposed to ineffective circular knitting, common in the industry) produces premium ...
(Date:5/4/2016)... ... May 04, 2016 , ... With the stamp of ... the month of May as National Cancer Research Month. According to the American ... of cancer with predications of one in four Americans dying as a result. , ...
(Date:5/4/2016)... ... 04, 2016 , ... International Conference on Obesity and Chronic ... at Las Vegas. It aims to bring together academicians, scientists, dietitians, surgeons, physicians, ... across the globe; making the conference a perfect platform to share experience and ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 4, 2016 Global ... pages, profiling 09 key companies and supported with ... and in-depth study on the current state of ... of the industry including definitions, classifications, applications and ... is provided for the international market including development ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology: